For: | Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656 [PMID: 38077159 DOI: 10.3748/wjg.v29.i41.5641] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm |
Number | Citing Articles |
1 |
Defne Cigdem Koc, Ion Bogdan Mănescu, Măriuca Mănescu, Minodora Dobreanu. A Review of the Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Nonhematologic Malignancies. Diagnostics 2024; 14(18): 2057 doi: 10.3390/diagnostics14182057
|
2 |
Ruotong Wang, Shaodi Wen, Xiaoyue Du, Jingwei Xia, Bowen Hu, Yihan Zhang, Guoren Zhou, Feng Jiang, Xiaomin Lu, Miaolin Zhu, Xinyu Xu, Bo Shen. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study. Cancer Medicine 2024; 13(17) doi: 10.1002/cam4.70228
|
3 |
Yuan Zhu, Ningning Kang, Li Zhang, Jianju Tao, Wen Xue, Hui Li, Yingcan Li, Xucai Zheng, Wei He, Junting Ma. Targeting and degradation of OTUB1 by Erianin for antimetastasis in esophageal squamous cell carcinoma. Phytomedicine 2024; 135: 155969 doi: 10.1016/j.phymed.2024.155969
|
4 |
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato. Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation. Expert Opinion on Drug Safety 2024; 23(6): 667 doi: 10.1080/14740338.2024.2348554
|